Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Change in Accured Expenses (2016 - 2025)

vTv Therapeutics' Change in Accured Expenses history spans 12 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 56.67% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.5 million, up 1005.33%, while the annual FY2025 figure was $1.5 million, 1005.33% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.7 million at vTv Therapeutics, up from -$326000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.4 million in Q1 2022 and bottomed at -$3.4 million in Q2 2024.
  • The 5-year median for Change in Accured Expenses is $230000.0 (2023), against an average of $212000.0.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 4675.0% in 2021 before it tumbled 2143.41% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.5 million in 2021, then fell by 3.21% to $1.4 million in 2022, then plummeted by 53.49% to $659000.0 in 2023, then surged by 483.76% to $3.8 million in 2024, then tumbled by 56.67% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Change in Accured Expenses are $1.7 million (Q4 2025), -$326000.0 (Q3 2025), and $1.0 million (Q2 2025).